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Abstract
Aims/hypothesis: Islet vascularization, by controlling beta-cell mass expansion in response to increased insulin demand, is
implicated in the progression to glucose intolerance and type 2 diabetes. We investigated how hyperglycaemia impairs
expansion and differentiation of the growing pancreas. We have grafted xenogenic (avian) embryonic pancreas in severe
combined immuno-deficient (SCID) mouse and analyzed endocrine and endothelial development in hyperglycaemic
compared to normoglycaemic conditions.
Methods: 14 dpi chicken pancreases were grafted under the kidney capsule of normoglycaemic or hyperglycaemic,
streptozotocin-induced, SCID mice and analyzed two weeks later. Vascularization was analyzed both quantitatively and
qualitatively using either in situ hybridization with both mouse- and chick-specific RNA probes for VEGFR2 or
immunohistochemistry with an antibody to nestin, a marker of endothelial cells that is specific for murine cells. To
inhibit angiopoietin 2 (Ang2), SCID mice were treated with 4 mg/kg IP L1–10 twice/week.
Results: In normoglycaemic condition, chicken-derived endocrine and exocrine cells developed well and intragraft vessels
were lined with mouse endothelial cells. When pancreases were grafted in hyperglycaemic mice, growth and differentiation
of the graft were altered and we observed endothelial discontinuities, large blood-filled spaces. Vessel density was
decreased. These major vascular anomalies were associated with strong over-expression of chick-Ang2. To explore the
possibility that Ang2 over-expression could be a key step in vascular disorganization induced by hyperglycaemia, we
treated mice with L1–10, an Ang-2 specific inhibitor. Inhibition of Ang2 improved vascularization and beta-cell density.
Conclusions: This work highlighted an important role of Ang2 in pancreatic vascular defects induced by hyperglycaemia.
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Introduction
Insulin-producing beta-cells and endothelial cells in the
pancreatic islets of Langerhans exchange bidirectional signals that
are necessary for development, differentiation and proper function
of both endocrine and vascular compartments [1]. Various beta-
cell-secreted angiogenic factors, like vascular endothelial growth
factor (VEGF) [2,3,4], are crucial for maintaining a dense and
fenestrated capillary network that affords proper insulin secretion
[5]. With regards to VEGF receptors, while vessels of the exocrine
tissue express the inactive (VEGF-R1) isoform, islet endothelial
cells express the active (VEGFR2) isoform [2,6]. Beta-cells
produce several other pro-angiogenic but also anti-angiogenic
factors, like angiopoietin-1 (Ang1) and thrombospondin-1 (Tsp1),
respectively. While Ang1-deficient mice are non-viable, due to
severe vascular defects [7], Tsp1-null mice have large and highly
vascularized islets [8]. Mutant mice lacking the two insulin genes
also exhibit increased pancreatic vascularization without change in
VEGF and VEGFR2 expression [9]. Conversely, islet endothelial
cells act on endocrine cells. During early pancreatic development,
vascular endothelial cells are key inducers for islet differentiation
[10] and, endothelial cell signals, such as those involved in matrix-
integrin interaction, modulate beta-cell proliferation and function
[11,12].
In situations such as pregnancy, postnatal development, obesity
or insulin resistance, islet mass adapts to increased insulin demand
[13]. During pregnancy, islet endothelial-cell secreted hepatocyte
growth factor stimulates beta-cell proliferation by downregulating
Tsp1 [14]. In type 2 diabetes, the possibility that hyperglycaemia
itself further affects beta-cell mass via islet endothelial cell
alterations received little attention until now [1]. However,
alterations of vasculature exist in several type 2 diabetes animal
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increase in the mean and diversity of capillary size, associated with
pericapillary oedema, fibrosis and irregularity of the endothelial
luminal surface [15,16]. Likewise spontaneously (nonobese)
diabetic Goto-Kakizaki rats have deficient islet vascularization
from neonatal life to adulthood [17]. GK rats show progressively
signs of islet endothelial activation, inflammation, vessel alter-
ations, fibrosis and of beta-cell loss [18]. Islet endothelium
alterations may be early events in the pathogenesis of hypergly-
caemia as they have also been observed in both prediabetic
(nonobese) Torii and Zucker diabetic fatty (ZDF) rats [19,20]. In
intrauterine growth restriction animals, which are prone to insulin
resistance, obesity, and type 2 diabetes, the reduction of islet
vascular density precedes that of beta-cell mass by several weeks
[21]. Neonatal exendin-4 treatment of these rats normalizes islet
vascular density, by increasing VEGF protein and prevents beta-
cell mass deterioration and diabetes onset [21,22].
Therefore, islet vascularization appears to be a key element in
the control of beta-cell mass expansion to increased insulin
demand [1]. Here, we investigated how hyperglycaemia impairs
expansion and differentiation of the growing pancreas, using the
xenogenic (avian) embryonic pancreas grafting under Severe
Combined Immuno-Deficient (SCID) mouse kidney capsule.
Avian models have been useful in morphogenesis and organogen-
esis studies [23] and chick pancreas developmental biology shares
many similarities with that of mammals [24,25]. Grafting of
embryonic chick pancreas in SCID mice allowed us to
characterize the avian or murine origin (pancreatic or vascular)
of growth signals and to identify and differentially modulate some
of them, to dissect their role during hyperglycaemia.
Results
Pancreatic chimeras consisting of chicken-derived
endocrine and exocrine cells and vessels with endothelial
cells of murine origin
In embryonic chick pancreas at 14 dpi before graft, we detected
few endocrine cells using anti-insulin and anti-glucagon antibodies
[26] and rare exocrine cells using an anti-amylase antibody (data
not shown). Fourteen-dpi chick pancreas were grafted under the
kidney capsule of normoglycaemic SCID mice (Fig. 1) and
analyzed 2 weeks later (Fig. 2.A and B). Under normoglycaemia,
the average size of the transplanted chick pancreas had increased
by 3.8 fold as compared to 14 dpi pancreas (75632 mm
2 before,
n=3 and 287627 mm
2 after, n=4, p,0.01). Endocrine and
exocrine differentiation was maintained (Fig. 3.A–C). Grafts were
well vascularized as observed macroscopically (Fig. 2.B) and
microscopically (Fig. 2.C–E). Vessels were filled with erythrocytes,
confirming their functionality (Fig. 2.C). The use of species-specific
probes for immunohistochemistry (Fig. 2.D) or in situ hybridization
(Fig. 2.E) led to characterize the origin of the graft vascularization.
In situ hybridization revealed the expression of c-VEGFR2 in
14 dpi chick pancreas before graft but not in 2 weeks grafts (data
not shown. In contrast m-VEGFR2 that was not detected in
pancreatic vessels before graft was clearly expressed on most
vessels 2 weeks after graft (n=6, Fig. 2.E). Nestin, a marker for
mouse endothelial cell, never detected endothelial cells of avian
origin by immunohistochemistry (data not shown), confirmed the
murine origin of proliferative vessels within grafts (n=4, Fig. 2.D).
The pattern of nestin staining observed in pancreatic graft was
similar to that of Von Willebrand Factor and CD31 staining (data
not shown). We have thus created chimeras consisting of chicken-
derived endocrine and exocrine cells and vessels with endothelial
cells of murine origin.
Hyperglycaemia induced pancreatic vascular anomalies
and increased angiopoietin 2
Hyperglycaemia was induced by a single STZ injection to SCID
mice. During the two weeks of grafts, STZ injected SCID mice
were hyperglycaemic as compared to citrate buffer control SCID
mice (Fig. 1). We did not detect effect of the graft on blood glucose
levels of recipients.
Effect of hyperglycaemia on angiogenesis was examined 2 weeks
after graft of 14 dpi chick pancreas under the kidney capsule of
diabetic SCID mice. The average pancreas size was not altered by
hyperglycaemia (287627 mm
2, control, n=4; 384654 mm
2,
hyperglycaemic, n=5). However, hyperglycaemia increased
beta-cell density by 35 fold, as compared to normoglycaemia
(Fig. 3.D). Pancreatic vasculature was overtly disorganized. All
grafts exhibit macroscopic haemorrhages (Fig. 2.F). At the
microscopic level, these haemorrhages were observed as large
blood-filled spaces (Fig. 2.G). Many of these pancreatic vascular
structures were only partly surrounded by endothelial cells,
(Fig. 2.H). We thus quantified the vascular compartment by
assessment of erythrocyte area and found that hyperglycaemia
increased the total area of vascular compartment by 9 fold
(Fig. 2.J). By contrast, endothelial cell density was decreased by
hyperglycemia, as assessed after either nestin immunohistochem-
istry (Fig. 2.H and K) or in situ hybridization with the mouse-
specific VEGFR2 probe (Fig. 2.I and L).
Abnormal expression of pro-angiogenic factors (VEGF, Ang1)
or anti-angiogenic factors (Tsp1, Ang2) might trigger these
hyperglycaemia-induced vessel alterations. In situ hybridization,
hardly detected expression of mVEGF, cVEGF, Tsp1, mAng2 and
cAng2 in normoglycaemic grafts (Fig. 4.A, D, G and J). While
hyperglycaemic condition did not alter mVEGF (Fig. 4.B and C),
cVEGF (Fig. 4.E and F) and Tsp1 expression (data not shown),
hyperglycaemia increased mAng2 (Fig. 4.H and I) and cAng2
expression (Fig. 4.K and L). We next investigated the respective
roles of VEGF and Ang2, in hyperglycaemia-induced alterations
of angiogenesis.
Figure 1. Blood glucose concentrations of SCID mice during
the 2 weeks post-graft of chicken pancreas. Continious line, white
square: control mice, n=12. Continious line, black square: STZ mice,
n=7. Dotted line, white square: L1–10 treated control mice, n=5.
Dotted line, black square: L1–10 treated STZ mice, n=5. Mice were used
for grafting experiments between 3 to 5 days after STZ or citrate buffer
injections. *** p,0.001 control and L1–10 treated control mice vs STZ
and L1–10 treated STZ mice. $ p,0.05, $$$ p,0.001 control mice vs: L1–
10 treated control mice.
doi:10.1371/journal.pone.0029438.g001
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not counteract hyperglycaemic induced vascular defects
A major advantage of chick tissues is the susceptibility to avian-
specific retroviruses. Replication-competent ASLV long terminal
repeat with a Splice acceptor (RCAS) vectors are powerful tools to
introduce and over-express genes specifically in avian tissues [27].
The first approach was to specifically over-express VEGF in
pancreatic grafts, using an avian-specific retrovirus RCAS carrying
the gene encoding the VEGF (RCAS-VEGF). Pancreata were
infected in vitro just before grafting. VEGF over-expression did not
improve significantly pancreatic angiogenesis in hyperglycaemic
SCID mice, as evidenced by nestin staining quantification (Fig. 5.C
and D). The vasculopathy pattern of these grafts was similar to
that of untreated pancreata. Because VEGF over-expression did
not decrease Ang2 expression in hyperglycaemic conditions (data
not shown), we hypothesized that Ang2 over-expression may be
directly involved in these vessels defects.
Inhibition of Ang2 improved vascular anomalies in
hyperglycaemic pancreas
To explore this possibility, we treated SCID mice, twice-a-
week during the 2 weeks following grafts, with 4 mg/kg i.p. of
L1–10, an Ang-2 specific inhibitor [28,29]. In normoglycaemic
conditions, inhibition of Ang2 had no effect on graft development
and vascularization (data not shown). By contrast, L1–10
treatment improved pancreatic vascularization in hyperglycaemic
SCID mice (Fig. 6), based on the following facts: 1) L1–10
treatment decreased by 5-fold the large blood-filled pancreatic
spaces of hyperglycaemic mice, as assessed by quantification of
erythrocytes density per vessel (Fig. 6.A); 2) nestin-positive
pancreatic endothelial cell numbers were increase in hypergly-
caemic L1–10 treated mice (Fig. 6.B); 3) there were also less vessel
discontinuities; 4) and finally, there was a concomitant, increase
in beta-cell density in L1–10-treated hyperglycaemic SCID mice
(Fig. 6.C).
Figure 2. Graft of embryonic chick pancreas under SCID mouse kidney capsule. At 14 dpi embryonic chick pancreas (A) was grafted under
the kidney capsule of a normoglycaemic SCID mouse and analyzed 2 weeks post-transplantation (B). At that time, hematoxylin-eosin coloration (C)
enabled us to observe many vessels filled with erythrocytes (arrow). Immunohistochemistry for nestin (D) and in situ hybridization for mouse VEGFR2
probe (E) indicated the murine origin of endothelial cells in the pancreatic graft. In hyperglycaemic conditions (F–I), dark spots were present on the
top of the pancreatic grafts (F). Vascularization was disorganized with large blood-fill spaces (G, arrow) associated with vessel discontinuities (H,
insert). Morphometry analyses of erythrocytes staining (G), nestin immunohistochemistry (H) and mouse VEGFR2 in situ hybridization (I) showed a
decreased number of endothelial cells (J, K and L). Student t-test *p,0.05, n=4–6.
doi:10.1371/journal.pone.0029438.g002
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Pancreatic epithelia and vessels have strong reciprocal influ-
ences [1]. To study their interactions during pancreas develop-
ment in normo- and hyperglycaemic conditions, we grafted
embryonic chick pancreata under SCID mouse kidney capsules.
It is possible with this methodology to characterize the origin,
avian (pancreatic) or murine (vascular), of the growth factors
involved and to modulate them specifically. We observed during
normoglycaemic conditions that the vessels penetrating the graft
were from the host after characterization using both in situ
hybridization with both mouse- and chick-specific VEGFR2
probes and immunohistochemistry for nestin, a specific mouse
endothelial cell marker. Graft vascularization by recipient’s vessels
and endothelial cells has been previously demonstrated in
particular in islets xenografts studies [30] and metanephroi
transplantation experiments [31]. Second, we observed major
vascular anomalies in the grafted pancreas of hyperglycaemic
SCID mice, including endothelial discontinuities, large blood-filled
spaces and decreased vessel density. We then studied the
expression of pro- or anti-angiogenic factors potentially involved
in this hyperglycaemia-induced vasculopathy. While expression of
both VEGF and Tsp1 was not altered, that of Ang2 was strongly
upregulated and may have been causal in vascular defects. In a
second set of experiments, to improve vascular defects, we first
over-expressed VEGF specifically in the graft, not in the whole
diabetic mice, by using a RCAS expression vector. This failed to
improve vascularization. We then focused on the anti-angiogenic
factor Ang2. We treated mice with L1–10 a specific Ang2 inhibitor
[29]. Ang2 inhibition corrected the vascular defects, suggesting
that Ang2 may be involved in hyperglycaemia-induced pancreatic
vasculopathy.
There are numerous similarities in vascular abnormalities
presented by mice experiencing high Ang2 levels and those we
observed in pancreatic grafts submitted to hyperglycaemia.
Transgenic mice over-expressing Ang2 exhibit vessel discontinu-
ities, with detachment of the endothelium from the underlying
mesenchyme and widespread vessel discontinuities [32]. Chronic
systemic Ang2 delivery to mice alters blood vessels anatomy both
qualitatively and quantitatively [33]. Several studies have shown a
Figure 3. Endocrine and exocrine differentiation in normo and hyperglycaemic pancreas. Insulin (A, D), glucagon (B, E) and amylase (C, F)
positive-cells in 2 weeks grafted pancreata in normoglycaemic (A–C) and hyperglycaemic conditions (D–F). Quantification of insulin (G), glucagon (H)
and amylase (I) positive-cells density. Hyperglycaemia increased beta-cell density (G). Student t- test *p,0.05, n=3–5.
doi:10.1371/journal.pone.0029438.g003
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Ang1, levels are elevated in plasma patients with type 2 diabetes
and this increase correlates with myocardial damage [34,35].
Circulating levels of Ang2 are significantly higher among diabetic
treated with insulin, i.e. those who have the highest insulin
secretory defects [36]. Expression of Ang2, and not that of Ang1, is
also increased in the heart of STZ-hyperglycaemic mice with or
without myocardial ischemia [37] and in db/db mice after
myocardial ischemia [38]. As reviewed by Hammes et al., chronic
hyperglycemia induces upregulation of Ang2 in retinal endothelial
cells and Mu ¨ller cells, leading to retinal pericyte detachment,
migration, apoptosis, and progressive vasoregression [39]. Type 2
diabetic mice show increased Ang2 expression in the ischemic
brain after stroke [40]. Finally, impaired wound healing is
associated with increased Ang2 protein expression in db/db mice
and STZ-hyperglycaemic rats [41,42]. In these studies, Ang1
protein expression was not increased.
Several hypotheses can be made on the role of Ang2 in diabetic
vasculopathy. First, Ang2 alone may exert pro-angiogenic activity
[32]. Second, high Ang2 levels may destabilize vessel walls and
consequently favor VEGF action and/or reduce the threshold
level for VEGFR2 activation and signaling [33]. Indeed over-
expression of VEGF itself has been associated with vascular
abnormalities [43]. We blocked Ang2 action by using L1–10, an
Figure 4. In situ hybridization of angiogenic factors in pancreatic grafts after 2 weeks hyperglycaemia. Expression of mouse VEGF (A, B),
chick VEGF (D, E), mouse Ang2 (G, H) and chick Ang2 (J, K) probes in normoglycemic (A, D, G, J) and hyperglycaemic grafts (B, E, H, K) was analyzed by
in situ hybridization. C, F, I and L, semi-quantification of labeling intensity between normoglycaemic and hyperglycaemic conditions. Ang2
expressions were increased by hyperglycaemia. Student t-test, **p,0.01, ***p,0.001, n=5.
doi:10.1371/journal.pone.0029438.g004
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was only and strongly expressed in the graft (A). In B, a photograph of a RCAS-VEGF-infected and grafted pancreas after 2 weeks hyperglycaemia
showed the presence of blood filled spaces. In C, nestin immunohistochemsitry in VEGF-over-expressing and grafted pancreas after 2 weeks in
hyperglycaemic conditions and in D, morphometry analyses of nestin immunohistochemistry (n=4).
doi:10.1371/journal.pone.0029438.g005
Figure 6. L1–10- induced specific Ang2 inhibition in hyperglycaemic conditions. During the 2 weeks post-graft, STZ-induced diabetic SCID
mice received L1–10 (4 mg/kg, twice-a-week). Pancreata were then collected (A) and vascularization was analyzed by hematoxylin-eosin staining (B)
and nestin immunohistochemistry (C). Large blood-filled spaces were decreased by L1–10 treatment (E). Insulin staining (G) showed a trend towards
increased b-cell density by L1–10 treatment.
doi:10.1371/journal.pone.0029438.g006
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inhibit tumor development [28,29]. L1–10 is a compound related
to L1–7, which was used in previous studies and shown to be a
specific inhibitor of Ang2 [29]. When measuring the neutralization
of the angiopoietin:Tie2 interaction, L1–10 showed .1000-fold
selectivity for Ang2 over Ang1. L1–10 was also recently shown to
correct vascular abnormalities associated with Ang2 over-expres-
sion in transgenic mice over-expressing the forkhead box C2 in
adipose tissue [44]. In our work, L1–10 improved pancreatic
development, differentiation and vascularization in hyperglycae-
mic conditions, suggesting that Ang2 may have causal in our
settings.
As type 2 diabetic patients exhibit increased levels of circulating
Ang-2 [36], we hypothesized that Ang2 could impact on
pancreatic vascularization during type 2 diabetes. Ang2, is
expressed during normal pancreas development [45]. Ang2 is
highly correlated with vascular inflammation in lupus [46],
psoriasis [47] and rheumatoid arthritis [48]. Transplantation of
islets of Langerhans is an emerging treatment procedure for
patients with severe type 1 diabetes. After an initial avascular
engraftment period [49], islets grafts become revascularized from
both intra-islet and recipient-derived endothelial cells [30,50].
Acquired vasculature has a lower vessel density compared with the
endogenous islets [51]. In animal models, therapies that enhance
the angiogenic capacity of islets by over-expression of VEGF-A,
Ang1 increase the vascular density of islet grafts and improve
metabolic function [3,52]. When islets were pre-cultured for 7
days, they expressed Ang2 [53]. Glucotoxicity is regularly
hypothesized to be a factor affecting the outcome of islet
transplantation, acting through altered angiogenesis [54,55].
Exposure to hyperglycemia at the beginning of the graft could
alter the revascularization process and impact on islet survival and
implication of Ang2 still need to be investigated.
This work highlighted an important role of Ang2 in pancreatic
vascular defects induced by hyperglycaemia. As inhibition of Ang2
improved vascularization and beta-cell density, Ang2 contribution
to othermodelsof type2 diabetes and inaltered revascularization of
grafted pancreatic islets in type 1 diabetes should be investigated.
Methods
Ethics Statement
This study was carried out along the principles of laboratory
animal care, experiments were approved by INSERM (the French
National Institute of Health) and was approved by the institutional
research ethics committee (Animalhouse agreement number B 75-
05- 12; SC permit number B75-1571).
Animals and pancreatic graft under the kidney capsule
Seven-week-old female SCID mice were obtained from Charles
River (L’Arbresle, France) and kept in the animal house of College
de France. One week after arrival, diabetes was induced by a
single intraperitoneal injection (i.p.) of streptozotocin (STZ, Sigma
Aldrich, Saint Quentin Fallavier, France) freshly dissolved in
0.1 mol/l citrate buffer at pH 4.5 and delivered at a dose of
160 mg/kg. Control SCID mice were injected with an equal
volume (100 ml) of citrate buffer. Blood glucose concentration was
measured using a Free style Papillon reflectance meter (Abbott,
Rungis, France) on samples collected from the tail vein. Diabetes
was defined as blood glucose levels consistently exceeding
200 mg/dl (Fig. 1). Mice were used for grafting experiments
between 3 to 5 days after STZ or citrate buffer injections.
Fertilized White Leghorn chicken eggs were incubated at
37.9uC in a humidified atmosphere (.60% relative humidity) as
previously described [26]. At the 14
th day postincubation (dpi),
chick pancreas was microdissected and immediately grafted under
the kidney capsule of SCID mice, which were anesthetized by a
ketamine/xylazine mix (Imalgen 1000, 120 mg/kg, Merial, Lyon,
France; Rompun, 6 mg/kg, Bayer Pharma, Puteaux, France).
Mice were sacrificed 2 weeks later and the grafted kidney was
collected for histology analyses. Blood glucose levels were followed
every 2–3 days during these two weeks.
Retroviral infection of embryonic chick pancreas with
RCAS-VEGF
We used the plasmid construct VEGF expressed by the avian
retrovirus vector RCAS (RCAS-VEGF) a gift from Peter Vogt
[56]. RCAS retroviruses were produced from chick embryonic
fibroblasts as previously described [57]. Embryonic chick-pancre-
ata were infected in vitro during one hour with RCAS-VEGF, just
before grafting.
Histochemistry
Chick pancreas either before graft (at 14 dpi) or 2 weeks after
graft (pancreas on kidney) were fixed for 1 and 4 h, respectively, in
4%-paraformaldehyde and processed for paraffin embedding.
Each pancreatic block was serially sectioned (7 mm) throughout
this length and was then mounted on slides.
Immunohistochemistry
Endocrine and exocrine tissues were stained using guinea pig
polyclonal anti-insulin (1/200; Dako, Glostrup, Denmark), rabbit
polyclonal anti-glucagon (1/200; Dako) or rabbit polyclonal anti-
alpha amylase (1/200; Sigma, Saint-Louis, Missouri, USA)
primary antibodies. Then, we added biotinylated anti-guinea pig
or anti-rabbit antibodies (1/200; Vector) as secondary antibodies,
followed by the use of Vectastain ABC kit (Vector) and
diaminobenzidine (DAB). Endothelial cells were immunostained
with anti-nestin primary antibody (1/50; Santa Cruz Biotechnol-
ogy, Santa Cruz, California, USA), after an antigen retrieval
induced by microwave pretreatment in 10 mmol/L citrate buffer
(pH 6). Slides were then incubated with the tyramide amplification
signal (TSA kit, Perkin Elmer, Courtaboeuf, France) and staining
was revealed using DAB. Nestin is a specific marker for pancreatic
endothelial cells and, in particular, proliferative endothelial cells
[19]. To observe erythrocytes, slides were stained with hematox-
ylin/eosin.
Morphometry
Immunohistochemistry morphometry analyses were performed
using iVison program (iVision-Mac, version 4.0.7, Biovision
technologies, Exton, PA) on 6–8 sections per pancreas from 3–5
animals. Average size of pancreas was expressed in mm
2. Beta-cell
density was expressed as the ratio of average beta-cell surface on
total pancreas surface, vascular density as the ratio of average
nestin-stained vessel surface on pancreas total surface and
erythrocyte density as ratio of average erythrocyte-filled vessel
surface on total vascular nestin-stained compartment.
In situ hybridization
In situ hybridization was performed as previously described on
paraffin sections [58]. The antisense and sense probes used
chicken (c)-Ang2, mouse (m)-Ang2, cVEGF, mVEGF, hu-
manTsp1, cVEGFR2 and mVEGFR2 have been previously
described [26,28,59,60]. In situ hybridization analyses were
assessed by semi-quantitative scoring and were expressed in
arbitrary units (a.u.).
Ang2-Induced Pancreatic Vascular Defects
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L1–10, an FC-fusion protein Ang2-specific inhibitor [29] was
kindly provided by Amgen, (Thousand Oaks, CA). L1–10, 4 mg/
kg in PBS was injected i.p. twice- a-week from the day of graft
onwards to the day of sacrifice (14 dpi).
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